CA-CLOUDLINUX-INC
2.6.2021 14:26:12 CEST | Business Wire | Press release
CloudLinux Inc., the team behind creating the popular CloudLinux operating system used extensively in the hosting community, announces the release of CloudLinux OS Solo. This is a new step for the hosting market, a new low-cost operating system that optimizes Linux server and application performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005624/en/
Direct speech from CloudLinux Product team:
What was the motivation behind developing a new Operating System?
“Our starting point was clear. Based on research results, our clients overwhelmingly want the classic CloudLinux OS with VPS and VMs, which only a few users can then utilize. One main request is a robust set of CloudLinux features on one server at affordable prices. Consequently, we found hundreds of VPSs with five or fewer websites hosted by a single client, many of which use VMs for staging and production. Some clients want a stable OS with technical support that is secure and not open-sourced.”
CloudLinux OS Solo is a low-cost Linux OS for small businesses and any individual with just one hosting account which is maintained with 24/7 support. It is optimized for website and server performance, with features most needed to maintain online business stability.
What does the new CloudLinux OS Solo do? It detects server and website performance bottlenecks that can slow down customer business flow. There is also a substantial array of notifications and alerts that help users quickly detail server performance issues.
Moreover, the new OS focuses on domains' availability and responsiveness and has a PHP Slow Site analyzer that generates daily reports for the server administrator with information about the top slow PHP-based URLs for all domains. And PHP X-Ray identifying the slow CMS plugins, which ultimately speeds up the website. The new CloudLinux OS Solo also shows detailed information about database errors caused by slow queries, fixes code that causes slow functions, and slow external calls.
More features focused on website optimization will be available soon with the CloudLinux OS Solo. For example, single-click WordPress optimization will increase productivity, and together with Smart Advice, will help to improve website performance metrics, which is so important for online businesses.
Who will use CloudLinux OS Solo? Hosting providers who provide VPS and want to increase the upsell opportunities, product portfolio expansion, and a decrease in performance complaints. Small businesses and any individual with just one hosting account who want to speed up their online business and care about SEO metrics, value a fast and optimized website from a high-performed web server. CloudLinux OS Solo is fully automated (works out of the box), has 24/7 support from trusted vendor CloudLinux, and is compatible with all popular hosting software.
About CloudLinux Inc.
As an industry leader, CloudLinux persistently keeps up with server security issues that influence Linux server device stability and availability. Based in Palo Alto, California, the heart of Silicon Valley, CloudLinux develops a strengthened Linux distribution.
CloudLinux offers live security patching for all Linux kernels and extended support options for all distros. The robust Linux product offerings increase server security and software used by enterprises, service providers, governments, and universities worldwide.
To date, CloudLinux Inc. has over 500,000 product installations with more than 4,000 customers and partners globally. As a top provider of Linux-based software options, CloudLinux, prides itself on industry-leading customer service supported by technicians with 450 years of combined Linux experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005624/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom